pharma news today obesity drugs glp-1 october 2025 Big in medicine! CMS has announced the BALANCE Model to expand access to obesity medications and support for Medicare/Medicaid populations, and the FDA approved the first oral for weight The Massachusetts Group Insurance Commission

Tirzepatide 15mg weekly (SURMOUNT-1) produced 20.9% at 72 weeks a 40% greater effect

To further validate this hypothesis, we used 2-deoxy-8-oxoguanosine (8-OHdG) and 4-hydroxynonenal (4-HNE) staining to evaluate the oxidative damage and lipid oxidation in SN TH neurons

Most cosmetic products are formulated for facial use, but body application is fine

The doses of sulfonylurea and/or insulin may need to be reduced

Try Setu Skin: Renew FIZZ risk-free with our 60-day money-back guarantee

Skin photos, hair density, recovery quality these are easier to evaluate when you step back from active use and observe what persists